|Articles|August 10, 2022
Validation of ICON™ Automated Cell Counting and Viability Assay (August 2022)
Author(s)Advanced Instruments
This benchmarking study compares the Advanced Instruments Solentim ICON™ viability assay to the performance of a commercially available cell counter. The results demonstrate lower variation, increased precision, and time savings.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
2
AdvanCell Targets GI Cancer With Peptide-Driven Lead-212 Radiotherapy
3
Genentech Expands RNAi Pipeline Through Global Licensing Deal
4
Pfizer Phase IIb Data Support Monthly GLP-1 Dosing for Obesity
5